Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma

References

• Chow LQM, Longo DL. Head and Neck Cancer. N Engl J Med. 2020;382(1):60–72. doi:10.1056/NEJMra171571531893516
   PubMed Web of Science ®Google Scholar
• Sarode GS, Sarode SC, Maniyar N, Anand R, Patil S. Oral cancer databases: a comprehensive review. J Oral Pathol Med. 2018;47(6):547–556. doi:10.1111/jop.1266729193424
   PubMed Web of Science ®Google Scholar
• Sharma A, Kim JW, Paeng JY. Clinical analysis of neck node metastasis in oral cavity cancer. J Korean Assoc Oral Maxillofac Surg. 2018;44(6):282–288. doi:10.5125/jkaoms.2018.44.6.28230637242
   PubMed Web of Science ®Google Scholar
• Bugshan A, Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res. 2020;9:229. doi:10.12688/f1000research.22941.132399208
   PubMedGoogle Scholar
• Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28. doi:10.1038/s41392-020-0134-x32296047
   PubMed Web of Science ®Google Scholar
• Garza-Lombo C, Pappa A, Panayiotidis MI, Franco R. Redox homeostasis, oxidative stress and mitophagy. Mitochondrion. 2020;51:105–117. doi:10.1016/j.mito.2020.01.00231972372
   PubMed Web of Science ®Google Scholar
• Tubbs A, Nussenzweig A. Endogenous DNA damage as a source of genomic instability in cancer. Cell. 2017;168(4):644–656. doi:10.1016/j.cell.2017.01.00228187286
   PubMed Web of Science ®Google Scholar
• Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: to promote or to suppress? Free Radic Biol Med. 2017;104:144–164. doi:10.1016/j.freeradbiomed.2017.01.00428088622
   PubMed Web of Science ®Google Scholar
• Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7(6):e2253. doi:10.1038/cddis.2016.10527277675
   PubMed Web of Science ®Google Scholar
• Sullivan LB, Chandel NS. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2014;2:17. doi:10.1186/2049-3002-2-1725671107
   PubMedGoogle Scholar
• Marengo B, Nitti M, Furfaro AL, et al. Redox homeostasis and cellular antioxidant systems: crucial players in cancer growth and therapy. Oxid Med Cell Longev. 2016;2016:6235641. doi:10.1155/2016/623564127418953
   PubMed Web of Science ®Google Scholar
• Kim Y, Jang HH. The role of peroxiredoxin family in cancer signaling. J Cancer Prev. 2019;24(2):65–71. doi:10.15430/JCP.2019.24.2.6531360686
   PubMed Web of Science ®Google Scholar
• Rhee SG, Woo HA, Kang D. The Role of peroxiredoxins in the transduction of H2O2 signals. Antioxid Redox Signal. 2018;28(7):537–557. doi:10.1089/ars.2017.716728587524
   PubMed Web of Science ®Google Scholar
• Hampton MB, Vick KA, Skoko JJ, Neumann CA. Peroxiredoxin involvement in the initiation and progression of human cancer. Antioxid Redox Signal. 2018;28(7):591–608. doi:10.1089/ars.2017.742229237274
   PubMed Web of Science ®Google Scholar
• Ismail T, Kim Y, Lee H, Lee DS, Lee HS. Interplay between mitochondrial peroxiredoxins and ROS in cancer development and progression. Int J Mol Sci. 2019;20(18). doi:10.3390/ijms20184407
   Web of Science ®Google Scholar
• Song IS, Kim HK, Jeong SH, et al. Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci. 2011;12(10):7163–7185. doi:10.3390/ijms1210716322072940
   PubMed Web of Science ®Google Scholar
• Whitaker HC, Patel D, Howat WJ, et al. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. Br J Cancer. 2013;109(4):983–993. doi:10.1038/bjc.2013.39623880827
   PubMed Web of Science ®Google Scholar
• Liu Y, Kwon T, Kim JS, et al. Peroxiredoxin V reduces beta-Lapachone-induced apoptosis of colon cancer cells. Anticancer Res. 2019;39(7):3677–3686. doi:10.21873/anticanres.1351631262894
   PubMed Web of Science ®Google Scholar
• Peng L, Wang R, Shang J, Xiong Y, Fu Z. Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients. Oncotarget. 2017;8(9):15057–15070. doi:10.18632/oncotarget.1480128125800
   PubMedGoogle Scholar
• Ahn HM, Yoo JW, Lee S, et al. Peroxiredoxin 5 promotes the epithelial-mesenchymal transition in colon cancer. Biochem Biophys Res Commun. 2017;487(3):580–586. doi:10.1016/j.bbrc.2017.04.09428431931
   PubMed Web of Science ®Google Scholar
• Huang WS, Huang CY, Hsieh MC, et al. Expression of PRDX6 correlates with migration and invasiveness of colorectal cancer cells. Cell Physiol Biochem. 2018;51(6):2616–2630. doi:10.1159/00049593430562740
   PubMedGoogle Scholar
• Ramasamy P, Larkin, AM, Linge A, et al. PRDX3 is associated with metastasis and poor survival in uveal melanoma. J Clin Pathol. 2020;73(7):408–412. doi:10.1136/jclinpath-2019-20617331771972
   PubMed Web of Science ®Google Scholar
• Wang G, Zhong WC, Bi YH, et al. The prognosis of peroxiredoxin family in breast cancer. Cancer Manag Res. 2019;11:9685–9699. doi:10.2147/CMAR.S22938931814764
   PubMed Web of Science ®Google Scholar
• Xu R, Pan J, Mei J, Zhang Q. Systematic characterization of prognostic values of peroxiredoxin family in gastric cancer. Biomed Res Int. 2020;2020:3948183. doi:10.1155/2020/394818332382548
   PubMed Web of Science ®Google Scholar
• Sienko J, Teliga-Czajkowska J, Przytula E, Czajkowski K, Smolarczyk R, Nowis D. Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer. Ann Agric Environ Med. 2019;26(3):415–419. doi:10.26444/aaem/10589931559796
   PubMed Web of Science ®Google Scholar
• Lopez-Grueso MJ, Lagal DJ, Garcia-Jimenez AF, et al. Knockout of PRDX6 induces mitochondrial dysfunction and cell cycle arrest at G2/M in HepG2 hepatocarcinoma cells. Redox Biol. 2020;37:101737. doi:10.1016/j.redox.2020.10173733035814
   PubMed Web of Science ®Google Scholar
• Lee EY, Kang JY, Kim KW. Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-kappaB in oral squamous cell carcinoma. Oncol Lett. 2015;10(5):3129–3136. doi:10.3892/ol.2015.370526722300
   PubMed Web of Science ®Google Scholar
• Chuerduangphui J, Ekalaksananan T, Heawchaiyaphum C, Vatanasapt P, Pientong C. Peroxiredoxin 2 is highly expressed in human oral squamous cell carcinoma cells and is upregulated by human papillomavirus oncoproteins and arecoline, promoting proliferation. PLoS One. 2020;15(12):e0242465. doi:10.1371/journal.pone.024246533332365
   PubMed Web of Science ®Google Scholar
• Huang CF, Sun ZJ, Zhao YF, Chen XM, Jia J, Zhang WF. Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue. Oral Dis. 2011;17(3):328–334. doi:10.1111/j.1601-0825.2010.01730.x20796224
   PubMed Web of Science ®Google Scholar
• Irani S. Distant metastasis from oral cancer: a review and molecular biologic aspects. J Int Soc Prev Community Dent. 2016;6(4):265–271. doi:10.4103/2231-0762.18680527583211
   PubMedGoogle Scholar
• Zanoni DK, Montero PH, Migliacci JC, et al. Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol. 2019;90:115–121. doi:10.1016/j.oraloncology.2019.02.00130846169
   PubMed Web of Science ®Google Scholar
• Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931–947. doi:10.1038/nrd400224287781
   PubMed Web of Science ®Google Scholar
• Rhee SG. Overview on peroxiredoxin. Mol Cells. 2016;39(1):1–5. doi:10.14348/molcells.2016.236826831451
   PubMed Web of Science ®Google Scholar
• Heawchaiyaphum C, Pientong C, Phusingha P, et al. Peroxiredoxin-2 and zinc-alpha-2-glycoprotein as potentially combined novel salivary biomarkers for early detection of oral squamous cell carcinoma using proteomic approaches. J Proteomics. 2018;173:52–61. doi:10.1016/j.jprot.2017.11.02229199150
   PubMed Web of Science ®Google Scholar
• Nicolussi A, D’Inzeo S, Capalbo C, et al. The role of peroxiredoxins in cancer. Mol Clin Oncol. 2017;6(2):139–153. doi:10.3892/mco.2017.112928357082
   PubMed Web of Science ®Google Scholar
• Bai B, Lin Y, Hu J, et al. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients. Oncol Rep. 2019;41(3):1539–1548. doi:10.3892/or.2019.697730747220
   PubMed Web of Science ®Google Scholar
• Rolfs F, Huber M, Gruber F, et al. Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis. Cancer Res. 2013;73(11):3460–3469. doi:10.1158/0008-5472.CAN-12-436923576553
   PubMed Web of Science ®Google Scholar
• Sun CC, Dong WR, Shao T, et al. Peroxiredoxin 1 (Prx1) is a dual-function enzyme by possessing Cys-independent catalase-like activity. Biochem J. 2017;474(8):1373–1394. doi:10.1042/BCJ2016085128219939
   PubMed Web of Science ®Google Scholar
• Lu E, Hu X, Pan C, Chen J, Xu Y, Zhu X. Up-regulation of peroxiredoxin-1 promotes cell proliferation and metastasis and inhibits apoptosis in cervical cancer. J Cancer. 2020;11(5):1170–1181. doi:10.7150/jca.3714731956363
   PubMed Web of Science ®Google Scholar
• Sun QK, Zhu JY, Wang W, et al. Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. 2014;31(1):786. doi:10.1007/s12032-013-0786-224297309
   PubMed Web of Science ®Google Scholar
• Zheng MJ, Wang J, Wang HM, et al. Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell. Onco Targets Ther. 2018;11:7745–7761. doi:10.2147/OTT.S17500930464523
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu M, Yang P, Peng H. Peroxiredoxin 1 (PRDX1) suppresses progressions and metastasis of osteosarcoma and fibrosarcoma of bone. Med Sci Monit. 2018;24:4113–4120. doi:10.12659/MSM.90873629908016
   PubMed Web of Science ®Google Scholar
• Li HX, Sun XY, Yang SM, Wang Q, Wang ZY. Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer. Pathol Res Pract. 2018;214(5):655–660. doi:10.1016/j.prp.2018.03.02629673884
   PubMed Web of Science ®Google Scholar
• Jiang Y, Cao W, Wu K, et al. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus. J Exp Clin Cancer Res. 2019;38(1):365. doi:10.1186/s13046-019-1364-z31429766
   PubMed Web of Science ®Google Scholar
• Zhang N, Zeng L, Wang S, et al. LncRNA FER1L4 promotes oral squamous cell carcinoma progression via targeting miR-133a-5p/Prx1 axis. Onco Targets Ther. 2021;14:795–806. doi:10.2147/OTT.S27735133568918
   PubMed Web of Science ®Google Scholar
• Onishi M, Yamano K, Sato M, Matsuda N, Okamoto K. Molecular mechanisms and physiological functions of mitophagy. EMBO J. 2021;40(3):e104705. doi:10.15252/embj.202010470533438778
   PubMed Web of Science ®Google Scholar
• Guerra F, Arbini AA, Moro L. Mitochondria and cancer chemoresistance. Biochim Biophys Acta Bioenerg. 2017;1858(8):686–699. doi:10.1016/j.bbabio.2017.01.01228161329
   PubMed Web of Science ®Google Scholar
• Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326–338. doi:10.1038/s41568-019-0143-731053804
   PubMed Web of Science ®Google Scholar
• Yu W, Wu J, Ning ZL, Liu QY, Quan RL. High Expression of peroxiredoxin 1 is associated with epithelial-mesenchymal transition marker and poor prognosis in gastric cancer. Med Sci Monit. 2018;24:2259–2270. doi:10.12659/MSM.90872229656298
   PubMed Web of Science ®Google Scholar
• Cai AL, Zeng W, Cai WL, et al. Peroxiredoxin-1 promotes cell proliferation and metastasis through enhancing Akt/mTOR in human osteosarcoma cells. Oncotarget. 2018;9(9):8290–8302. doi:10.18632/oncotarget.2366229492195
   PubMedGoogle Scholar
• Niu W, Zhang M, Chen H, et al. Peroxiredoxin 1 promotes invasion and migration by regulating epithelial-to-mesenchymal transition during oral carcinogenesis. Oncotarget. 2016;7(30):47042–47051. doi:10.18632/oncotarget.970527259998
   PubMedGoogle Scholar
• Wang M, Niu W, Qi M, et al. Nicotine promotes cervical metastasis of oral cancer by regulating peroxiredoxin 1 and epithelial-mesenchymal transition in mice. Onco Targets Ther. 2019;12:3327–3338. doi:10.2147/OTT.S19412931118684
   PubMed Web of Science ®Google Scholar